Nvigen
NVIGEN, based in Sunnyvale, US, offers high-sensitivity magnetic nanobeads for cost-effective, high-yield NGS and clinical diagnostics.
Founded
2011NVIGEN, based in Sunnyvale, US, offers high-sensitivity magnetic nanobeads for cost-effective, high-yield NGS and clinical diagnostics.
Founded in Sunnyvale, US, NVIGEN is dedicated to advancing the field of molecular diagnostics through its innovative magnetic nanobead technology. The company's core mission is to enhance the sensitivity and yield of Next-Generation Sequencing (NGS) and clinical diagnostics, making these processes more efficient and cost-effective. NVIGEN's flagship products include MagVigen magnetic nanobeads, which offer 10x sensitivity and 10-100x yield improvements, and NERNST-Seq™ for RNA sequencing with spatial and temporal resolution. Their market focus spans from cancer liquid biopsies to COVID-19 virus detection.
NVIGEN has garnered attention through notable presentations at events such as SABCS23, where they unveiled their comprehensive liquid biopsy technology. The company collaborates with leading scientists and industry experts to push the boundaries of precision medicine. Key achievements include significant advancements in cancer profiling technologies and the development of high-throughput diagnostic assays. NVIGEN's impact is evident in its contributions to more accurate and accessible diagnostic solutions, positioning it as a pivotal player in the biotech industry.
Companies similar to Nvigen include Nexgenia, NuProbe, Nanogen and Nanopath.
Nvigen was founded in 2011.
Nvigen's headquarters is located in Sunnyvale, CA, US.
Nvigen's most recent funding round was for $1.1M (USD) in March 2014.
As of Mar 18, 2014, Nvigen has disclosed funding of $1.1M (USD). Undisclosed round amounts are excluded.
Nvigen has 14 employees as of Feb 4, 2024.
Nanopath
nanopathdx.com
